There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view
et al., New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155, Jun 2023
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Discussion of censorship in scientific journals and the media; fraudulent, false, and misleading information used to justify censorship and the termination of trials; harassment of highly cited and respected researchers reporting life-saving research with results that are inconvenient for conflicted parties; and conflicts of interest including the correlation between the amount of money received from Gilead and public opposition to HCQ.
1.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
2.
Monsalve et al., NETosis: A key player in autoimmunity, COVID-19, and long COVID, Journal of Translational Autoimmunity, doi:10.1016/j.jtauto.2025.100280.
3.
Xie et al., The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.
4.
Gkioulekas et al., Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2, Tasman Medical Journal, 6:4, tasmanmedicaljournal.com/2024/10/use-of-hydroxychloroquine-in-multidrug-protocols-for-sars-cov-2a/.
5.
Gortler et al., Those Published “17,000 Hydroxychloroquine Deaths” Never Happened, Brownstone Journal, brownstone.org/articles/those-published-17000-hydroxychloroquine-deaths-never-happened/.
6.
Boretti et al., Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection, Coronaviruses, doi:10.2174/0126667975327612240902104505.
7.
Gortler (B) et al., Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America, Brownstone Journal, brownstone.org/articles/trumps-63-million-doses-of-hydroxychloroquine-could-have-been-great-for-america/.
8.
Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.
9.
Asaba et al., Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections, Journal of Inflammation Research, doi:10.2147/jir.s474707.
10.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
11.
Ali et al., SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication, Journal of Clinical Medicine, doi:10.3390/jcm12186079.
12.
Brouqui et al., There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view, New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155.
13.
Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.
14.
Boretti (B), A., Pharmacotherapy for Covid-19 infection in the countries of the Cooperation Council for the Arab States, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2021.08.005.
15.
Vigbedor et al., Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2021.110825.
16.
Kaur et al., Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?, Medical Hypotheses, doi:10.1016/j.mehy.2021.110539.
17.
Raoult, D., Rational for meta-analysis and randomized treatment: the COVID-19 example, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.012.
18.
Matada et al., A comprehensive review on the biological interest of quinoline and its derivatives, Bioorganic & Medicinal Chemistry, doi:10.1016/j.bmc.2020.115973.
19.
IHU, Natural history and therapeutic options for COVID-19, Expert Review of Clinical Immunology, www.mediterranee-infection.com/wp-content/uploads/2020/09/ERM-2020-0073.R1_Proof_hi.pdf.
20.
Hecel et al., Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?, Pharmaceuticals, 13:9, 228, doi:10.3390/ph13090228.
21.
Li et al., Is hydroxychloroquine beneficial for COVID-19 patients?, Cell Death & Disease volume 11, doi:10.1038/s41419-020-2721-8.
22.
Goldstein, L., Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys, Preprint, July 7, 2020, wattsupwiththat.com/2020/07/07/hydroxychloroquine-based-covid-19-treatment-a-systematic-review-of-clinical-evidence-and-expert-opinion-from-physicians-surveys/.
23.
Roussel et al., Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences, New Microbes and New Infections, Volume 38
, doi:10.1016/j.nmni.2020.100710.
24.
Mo et al., Chloroquine phosphate: therapeutic drug for COVID-19, Journal of Southern Medical University, doi:10.12122/j.issn.1673-4254.2020.04.22.
25.
Gao et al., Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus Disease 2019 (COVID-19), Biosci Trends, May 21, 2020, 14:2, 156-158, doi:10.5582/bst.2020.03072.
26.
Derwand et al., Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Medical Hypotheses, doi:10.1016/j.mehy.2020.109815.
27.
Sahraei et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, International Journal of Antimicrobial Agents, April 2020, 55:4, doi:10.1016/j.ijantimicag.2020.105945.
28.
Todaro et al., An Effective Treatment for Coronavirus (COVID-19), github.com/covidtrial/info/raw/master/An%20Effective%20Treatment%20for%20Coronavirus%20(COVID-19).pdf.
Brouqui et al., 22 Jun 2023, peer-reviewed, 3 authors.
There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view
New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of interest. None
Text Words: 1199
Online supplemental data There is no such thing as a Ministry of Truth and why it is important to challenge conventional "wisdom" -a personal view.
Authors
References
Andreani, Bideau, Duflot, Jardot, Rolland et al., In vitro testing of combined HCQ and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog
Ashour, Ivermectin, From theory to clinical application, Int J Antimicrob Agents
Axfors, Schmitt, Janiaud, Van't Hooft, Abd-Elsalam et al., Mortality outcomes with HCQ and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, Nat Commun
Bik, la déceleuse de fraudes scientifiques" qui critique constamment Didier Raoult, estelle au-dessus de tout soupçon ? | FranceSoir
Brouqui, Boudjema, Soto Aladro, Chabrière, Florea et al., New Approaches to Prevent Healthcare-Associated Infection, Clin Infect Dis
Brouqui, Drancourt, Raoult, on behalf of the IHU Task Force. COVID-19 Management at IHU Méditerranée Infection: A One-Year Experience, Journal of Clinical Medicine
Colson, Fournier, Chaudet, Delerce, Gatineau et al., Analysis of SARS-CoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics, Frontiers in Microbiology, doi:10.3389/fmicb.2021.786233
Didier, Au dela de l'affaire de la choroquine [Internet]. Michel Lafon. Michel Lafon; 2021 [cited
Dubée, Roy, Vielle, Parot-Schinkel, Blanchet et al., HCQ in mild-tomoderate coronavirus disease 2019: a placebo-controlled double blind trial, Clinical Microbiology and Infection
Elisha, Guetzkow, Shir-Raz, Ronel, Suppressing Scientific Discourse on Vaccines? Selfperceptions of researchers and practitioners
Elisha, Guetzkow, Shir-Raz, Ronel, Suppressing Scientific Discourse on Vaccines? Selfperceptions of researchers and practitioners
Gautret, Lagier, Parola, Hoang, Meddeb et al., HCQ and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, International Journal of Antimicrobial Agents
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Ivermectin, Covid-19, Treatment Guidelines
Lagier, Million, Cortaredona, Delorme, Colson et al., Outcomes of 2111 COVID-19 Hospitalized Patients Treated with HCQ/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis, Ther Clin Risk Manag
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with HCQ/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis
Lane, Weaver, Kostka, Duarte-Salles, Abrahao et al., Risk of HCQ alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study, Lancet Rheumatol
Liester, The Suppression of Dissent During the COVID-19 Pandemic. Social Epistemology Review and Reply Collective [Internet]
Mehra, Desai, Kuy, Henry, Patel, Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19, N Engl J Med, doi:10.1056/NEJMoa2007621
Mehra, Desai, Ruschitzka, Patel, RETRACTED: HCQ or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Million, Lagier, Tissot-Dupont, Ravaux, Dhiver et al., Early combination therapy with HCQ and azithromycin reduces mortality in 10,429 COVID-19 outpatients, Rev Cardiovasc Med
Niemiec, COVID-19 and misinformation: Is censorship of social media a remedy to the spread of medical misinformation? EMBO Rep
Orwell, Secker & Warburg
Orwell, Secker & Warburg
Raoult, Lancet gate: a matter of fact or a matter of concern. New Microbes New Infect
Recovery Collaborative Group, Horby, Mafham, Linsell, Bell et al., Effect of HCQ in Hospitalized Patients with Covid-19, N Engl J Med
Recovery Collaborative Group, Horby, Mafham, Linsell, Bell et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Roussel, Raoult, Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. New Microbes and New Infections
Sanchezruiz, Nuzum, Kouzi, Oral ivermectin for the treatment of head lice infestation, Am J Health Syst Pharm
Scola, Bideau, Andreani, Hoang, Grimaldier et al., Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards, Eur J Clin Microbiol Infect Dis
Shir-Raz, Martin, Ronel, Guetzkow, Censorship and Suppression of Covid-19 Heterodoxy: Tactics and Counter-Tactics, Minerva
DOI record:
{
"DOI": "10.1016/j.nmni.2023.101155",
"ISSN": [
"2052-2975"
],
"URL": "http://dx.doi.org/10.1016/j.nmni.2023.101155",
"alternative-id": [
"S2052297523000744"
],
"article-number": "101155",
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "New Microbes and New Infections"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.nmni.2023.101155"
},
{
"label": "Content Type",
"name": "content_type",
"value": "simple-article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2023 Published by Elsevier Ltd."
}
],
"author": [
{
"ORCID": "http://orcid.org/0000-0002-6125-2805",
"affiliation": [],
"authenticated-orcid": false,
"family": "Brouqui",
"given": "Philippe",
"sequence": "first"
},
{
"affiliation": [],
"family": "Drancourt",
"given": "Michel",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Raoult",
"given": "Didier",
"sequence": "additional"
}
],
"container-title": "New Microbes and New Infections",
"container-title-short": "New Microbes and New Infections",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinicalkey.fr",
"clinicalkey.jp",
"clinicalkey.es",
"clinicalkey.com.au",
"clinicalkey.com",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2023,
6,
22
]
],
"date-time": "2023-06-22T02:23:47Z",
"timestamp": 1687400627000
},
"deposited": {
"date-parts": [
[
2023,
6,
22
]
],
"date-time": "2023-06-22T02:23:52Z",
"timestamp": 1687400632000
},
"indexed": {
"date-parts": [
[
2023,
6,
22
]
],
"date-time": "2023-06-22T04:32:33Z",
"timestamp": 1687408353846
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2023,
6
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
6,
1
]
],
"date-time": "2023-06-01T00:00:00Z",
"timestamp": 1685577600000
}
},
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
6,
1
]
],
"date-time": "2023-06-01T00:00:00Z",
"timestamp": 1685577600000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S2052297523000744?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S2052297523000744?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "101155",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2023,
6
]
]
},
"published-print": {
"date-parts": [
[
2023,
6
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"author": "George",
"key": "10.1016/j.nmni.2023.101155_bib1",
"series-title": "Nineteen Eighty-Four (1984)",
"year": "1949"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
"author": "Gautret",
"doi-asserted-by": "crossref",
"issue": "1",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.nmni.2023.101155_bib2",
"volume": "56",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2022926",
"article-title": "Effect of hydroxychloroquine in hospitalized patients with Covid-19",
"author": "Horby",
"doi-asserted-by": "crossref",
"first-page": "2030",
"issue": "21",
"journal-title": "N Engl J Med",
"key": "10.1016/j.nmni.2023.101155_bib3",
"volume": "383",
"year": "2020"
},
{
"article-title": "Suppressing scientific discourse on vaccines? Self-perceptions of researchers and practitioners",
"author": "Elisha",
"first-page": "1",
"journal-title": "HEC Forum",
"key": "10.1016/j.nmni.2023.101155_bib5",
"year": "2022"
}
],
"reference-count": 4,
"references-count": 4,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S2052297523000744"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Infectious Diseases",
"Microbiology"
],
"subtitle": [],
"title": "There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy"
}